Abstract
2556 Background: Owing to the role of PARPs in DNA damage repair, PARP inhibitors (PARPi) are under clinical investigation as anticancer therapies with a focus on tumors with impaired homologous re...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
